Symbols

CAMP

CAMP4 Therapeutics·NASDAQ

--(--)

Market Open: --

--(--)

Pre-Market: --

Signals Analysis

Bullish signal 2

Bearish signal 2

Stock Price Surged Significantly

Consensus Rating "Buy"

EPS Below Expectations

Consecutive Revenue Decline

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About CAMP

Camp4 Therapeutics Corporation

A biopharmaceutical company that uses RNA based regulatory therapy to treat various genetic diseases in clinical stages

Industry

Biological Technology

Established Date

Invalid Date

Listing Date

10/11/2024

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.camp4tx.com

Security Type

Common stock

Office address

One Kendall Square, Building 1400 West, 3rd Floor, Cambridge, Massachusetts 02139

Business

Introduction

CAMP4 Therapeutics Corporation was originally incorporated in Delaware in 2015 and began operations in 2016. They are a clinical-stage biopharmaceutical company that has pioneered the discovery and development of RNA-based regulatory therapies designed to up-regulate gene expression and restore healthy protein levels for the treatment of various genetic diseases. Regulatory RNAs, or regRNAs, play a central role in the regulation of each protein-coding gene by promoting gene activation and suppression. Their method aims to amplify the expression of messenger RNA or mRNA by harnessing the power of regRNAs, which form local complexes with transcription factors and regulate gene expression. Their proprietary RNA drive platform, or RAP platform, enables them to rapidly and systematically identify and characterize the active regulatory elements that control each expressed gene and the tens of thousands of druggable enhancers and promoter regRNA sequences that control protein-coding genes.

Company Financials

EPS

CAMP has released its 2025 Q3 earnings. EPS was reported at -0.55, versus the expected -0.48, missing expectations. The chart below visualizes how CAMP has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

CAMP has released its 2025 Q2 earnings report, with revenue of 1.50M, reflecting a YoY change of NaN%, and net profit of -12.59M, showing a YoY change of -0.09%. The Sankey diagram below clearly presents CAMP's revenue sources and cost distribution.